Genitourinary Cancers: Molecular Determinants for Personalized Therapies

Recent insights and emerging strategies for individualized therapeutic approaches in patients with genitourinary (GU) cancers are based on patient's genomic and cancer's molecular profiles. This depends on the significant advances made in molecular biology technologies, such as next-generation sequencing and whole-exome sequencing. The rise of such novel techniques has grayly increased our knowledge on cancer cell biology and development, thus allowing to identify complex abnormalities at the genomic level. These findings have paved the way toward what is called precision medicine, thus providing healthcare from an individual perspective in patients with GU tumors.

[1]  A. Lopez‐Beltran,et al.  Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol 2015;68:912-4. , 2017, European urology.

[2]  H. Moch,et al.  An Overview of Emerging Immunotargets of Genitourinary Tumors. , 2016, Current drug targets.

[3]  R. Montironi,et al.  Emerging Immunotargets in Bladder Cancer. , 2016, Current drug targets.

[4]  J. Kucharczyk,et al.  Emerging Immunotargets in Metastatic Renal Cell Carcinoma. , 2016, Current drug targets.

[5]  H. Moch,et al.  Emerging Immunotargets and Immunotherapies in Prostate Cancer. , 2016, Current drug targets.

[6]  P. Stricker,et al.  68Ga‐PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment , 2016, BJU international.

[7]  R. Montironi,et al.  Immunotargeting and personalized therapies in genitourinary cancers. , 2016, Future oncology.

[8]  D. Geynisman.  Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. , 2015, European urology.

[9]  R. Montironi,et al.  Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. , 2015, Critical reviews in oncology/hematology.

[10]  C. Porta,et al.  PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. , 2015, Cancer treatment reviews.

[11]  H. Moch,et al.  Oncotargets in different renal cancer subtypes. , 2015, Current drug targets.

[12]  H. Moch,et al.  Molecular foundations for personalized therapy in prostate cancer. , 2015, Current drug targets.

[13]  H. Moch,et al.  Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview. , 2015, Current drug targets.

[14]  H. Moch,et al.  Bladder cancer: molecular determinants of personalized therapy. , 2015, Current drug targets.

[15]  R. Montironi,et al.  Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. , 2014, Journal of biological regulators and homeostatic agents.